Compare Limas Indonesia Makmur Tbk (LMAS) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Limas Indonesia Makmur Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Limas Indonesia Makmur Tbk trades at Rp50 (market cap 39.39B), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Organon Pharma Indonesia Tbk. is far larger — about 2.7× Limas Indonesia Makmur Tbk's market cap. Which is the better fit depends on your goals.
| LMAS | SCPI | |
|---|---|---|
Market Cap | 39.39B | 104.4B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Limas Indonesia Makmur Tbk
Based in Jakarta and established on June 4th 1996, Limas offers comprehensive financial information services for the financial sector. On 3rd quarter of 1999, S&P Comstocks, Inc appointed the Company as its strategic partner for its data distribution agent in Indonesia. On November 1999, the Company launched its first real time terminal product called StockWatch with extensive tools and coverage for trading on Jakarta Stock Exchange. On January 2000, Limas received endorsements from the Jakarta Stock Exchange to provide its members with the StockWatch terminal. Further endorsements were followed subsequently from Surabaya Stock Exchange to its members on March 2000. On June 2000, the Company launched www.e-bursa.com the first financial sites in local language bahasa. On December 2000, Limas partnered with Dow Jones Newswire to launch the first real time news in bahasa called Dow Jones Limas news. On September 2001, StockWatch version 2.1 was launched and was the first realtime terminal to provide live coverage on Futures trading on the Surabaya Stock Exchange.
Read more on LMAS →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
